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Background: Coffee consumption has been consistently associated with a lower risk of type 2 diabetes
mellitus in cohort studies. In addition, coffee components increased insulin sensitivity in animal models.
However, data from intervention studies on the effect of coffee consumption on glucose metabolism have
been limited by small sample sizes, lack of blinding, short follow-up duration and the use of surrogate
indices of insulin sensitivity. We designed the Coffee for Metabolic Health (COMETH) study to evaluate
the effect of coffee consumption on insulin sensitivity.
Methodology: The COMETH study is a double-blind randomized placebo-controlled 24-week trial. Par-
ticipants were overweight, male and female habitual coffee consumers who were of Chinese, Malay and
Asian-Indian ethnicity. We excluded smokers, persons with diabetes, and persons with low insulin
resistance (HOMA-IR < 1.30). Participants were randomly assigned to receive daily 4 cups of instant
regular coffee or 4 cups of a coffee-like placebo beverage. The hyperinsulinemic euglycemic clamp was
performed at baseline and at the end of 24 weeks to determine changes in the bodyweight standardized
M-value. Secondary outcomes included changes in fasting glucose and insulin sensitivity mediators such
as adiponectin, markers of inﬂammation, liver function, and oxidative stress.
We enrolled 128 participants, 126 (57.1% males; aged 35e67 years) of whom completed baseline
assessments.
Discussion: If improvement in insulin sensitivity in the coffee group is signiﬁcantly greater than that of
the placebo group, this would support the hypothesis that coffee consumption reduced risk of type 2
diabetes through biological pathways involving insulin sensitivity.
Trial registration: ClinicalTrials.gov identiﬁer: NCT01738399. Registered on 28 November 2012. Trial
Sponsor: Nestle Research Center, Lausanne, Switzerland. Trial Site: National University of Singapore.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Public Health, National Uni-
9, Singapore.
.sg (R.M. van Dam).
Inc. This is an open access article u1. Introduction
The global burden of type 2 diabetes mellitus (T2DM) [1], calls
for concerted efforts targeted at diabetes prevention. Insulin
resistance is a major pathway to the development of T2DM [2] and
it is inﬂuenced by both environmental and genetic factors [1]. Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
T2DM Type 2 diabetes mellitus
COMETH Coffee for metabolic health
BMI Body mass index
HOMA-IR Homeostasis model assessment of insulin resistance
DSRB Domain speciﬁc review board
NRC Nestle Research Center
PTC Product Technology Centre
GERD Gastroesophageal reﬂux disease
SCCS Singapore Consortium of Cohort Studies
SINDI-2 Singapore Indian Eye Study-2
SP2 Singapore Prospective Study Program
IL-6 Interleukin-6
IL-18 Interleukin-18
FFQ Food frequency questionnaire
IPAQ International physical activity questionnaire
CES-D Center for epidemiological studies depression scale
PROMIS Patient reported outcomes measurement information
system
NHANES National health and nutrition survey
IBS-SSS Irritable bowel syndrome-symptom severity scale
GDR Glucose disposal rate
M-value Metabolizable glucose-value
M/I ratio Metabolizable glucose-value standardized to average
steady-state plasma insulin levels
BW Bodyweight
FFM Fat free mass
Mbw Metabolizable glucose-value adjusted to bodyweight
Mffm Metabolizable glucose-value adjusted to fat free mass
M/Ibw Metabolizable glucose-value adjusted to bodyweight
and standardized to average steady-state plasma
insulin levels
M/Iffm Metabolizable glucose-value adjusted to fat free mass
and standardized to average steady-state plasma
insulin levels
MSC Space corrected M-value
M Uncorrected M-value
SC Space correction factor
UC Urinary correction factor
DXA Dual energy X-ray absorptiometry
QC Quality control
CONSORT Consolidated standards of reporting trials
ANCOVA Analysis of covariance
ITT Intention to treat
PP Per-protocol
WC Waist circumference
WHTR Waist-to-height ratio
LDL Low-density lipoprotein
HDL High-density lipoprotein
CISI Composite insulin sensitivity index
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a deterioration in diet quality [3], increase in obesity prevalence [2]
and reduction of physical activity [2]. Dietary prevention of T2DM
has largely focused on nutrients and food groups [3], but evidence
is emerging that the choice of beverages, such as coffee, can also
affect the development of T2DM.
Coffee is one of the most widely consumed beverages in the
world [4]. Clues to the potential beneﬁcial effect of coffee against
T2DM were ﬁrst published in 2002 [5]. Since 2002, more than 20
prospective cohort studies conducted in the U.S., Asia, and Europe
showed an inverse association between coffee intake and T2DM [6].
In a recent meta-analysis, coffee intake was inversely associated
with T2DM risk in a dose-dependent manner with 4 cups/day being
associatedwith a 25% lower risk [6]. Although observational studies
statistically adjusted for confounders, residual confounding by
unmeasured or imperfectly measured confounders may persist,
affecting the accuracy of results. Therefore, randomized trials are
needed to provide more conclusive evidence about the effect of
coffee on glucose homeostasis. In addition, trials can include
detailed measurements that provide insights into the biological
mechanisms that may underlie the putative effect of coffee on risk
of T2DM.
Data on the modulation of glucose homeostasis by coffee from
trials are limited. Limitations include small sample sizes, lack of a
suitable placebo beverage to facilitate blinding, short follow-up
periods, and the use of surrogate insulin sensitivity measures. In
the trials conducted by Kempf et al. [7] and Wedick et al. [8] that
evaluated 12 and 8 weeks of coffee consumption respectively, no
change in insulin sensitivity or glucose tolerance was observed, but
adiponectin levels signiﬁcantly increased after coffee consumption.
Ohnaka et al. [9], in a 16-week trial reported a decrease in 2-h
glucose levels after coffee consumption although no change in in-
sulin sensitivity was observed. In a crossover trial, van Dam et al.
[10] reported an increase in fasting insulin levels after very highcoffee consumption, which could reﬂect either an increase in in-
sulin resistance or reduced insulin clearance. Furthermore, by
assessing fasting hepatic glucose production in a 2-week random-
ized crossover trial, Lecoultre et al. [11] concluded that coffee
attenuated fructose-induced hepatic insulin resistance.
Thus, results from conducted coffee trials have been inconclu-
sive. We therefore designed the Coffee for Metabolic Health
(COMETH) study, a double-blind randomized trial, with an aim to
investigate the longer term (24 weeks) effects of coffee on insulin
sensitivity in overweight participants using the gold standard
technique of hyperinsulinemic euglycemic clamp. In addition, with
a larger sample size and a coffee-like placebo beverage to facilitate
masking, we sought to overcome the limitations of previous trials.
In this article, we describe the rationale, methodology and baseline
characteristics of participants in the COMETH study.2. Methodology
2.1. Aims and hypothesis
The primary aim of the COMETH study was to examine the ef-
fects of 24 weeks of regular coffee consumption on insulin sensi-
tivity in adults who were at higher risk of developing T2DM. We
hypothesized that participants randomized to receive coffee
(intervention group) would show a greater improvement in insulin
sensitivity as measured by the hyperinsulinemic euglycemic clamp,
and an improvement in mediators of insulin sensitivity after 24
weeks of coffee consumption, as compared to those receiving pla-
cebo (control group).
The secondary aims of the COMETH study were to examine the
effects of regular coffee on glycemia (i.e. fasting plasma glucose);
biological risk factors that may underlie a possible effect on insulin
sensitivity (i.e. adiponectin, non-esteriﬁed fatty acids, and markers
of inﬂammation, oxidative stress, liver function and renal function);
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health; and psychological health (fatigue and depression).2.2. Study design overview and ethics
COMETH was a single-center, randomized, double-blind, pla-
cebo-controlled intervention trial comparing regular consumption
of coffee and a coffee-like beverage in parallel (Fig. 1).
For 24 weeks, overweight and insulin resistant individuals aged
35e69 years, who satisﬁed our inclusion/exclusion criteria (see
section 2.4), were randomly assigned to receive either 4 sachets
(cups) of an instant regular coffee beverage (intervention) or 4
sachets (cups) of a coffee-like beverage (placebo) daily. The placebo
beverage mimicked the taste and color of coffee, thereby allowing
blinding to be possible. Being double-blind, neither the participants
nor the researchers knew the identity of the beverage each subject
consumed.
We used a variety of methods to recruit participants. Interested
participants were screened using a telephonic survey. ParticipantsFig. 1. Timeline and activities of the Coffee for Metabolic Health (COMETH) studwho successfully completed the initial screening were invited for
an in-person screening visit during which informed consent was
obtained, height, weight and blood pressure was measured, and
blood was drawn to measure glucose and insulin for homeostasis
model assessment of insulin resistance (HOMA-IR) [12] calcula-
tions. Individuals who were insulin sensitive (HOMA-IR < 1.30)
were excluded. Eligible participants who had a HOMA-IR  1.30
were invited for an orientation session, after which the participants
were asked to refrain from coffee for a period of 4 weeks (run-in
phase).
Following randomization to the respective intervention arms,
hyperinsulinemic euglycemic clamps were performed at baseline,
and at 24 weeks to measure insulin sensitivity. Questionnaire in-
formation, fasting blood samples, ﬁrst morning urine samples and
clinical measures were obtained at baseline, 12 weeks and 24
weeks. With an expected dropout rate of 20%, 104 out of a planned
number of 130 enrolled participants were anticipated to complete
the study.
The COMETH study was conducted in Singapore at a single site,y. Anthropometric measurements were performed at t ¼ 0 min in all visits.
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of Medicine, National University of Singapore.
Our study was conducted according to the principles and rules
laid down in the Declaration of Helsinki and its subsequent
amendments. The study was approved by the Domain Speciﬁc
Review Board (DSRB) of the National Healthcare Group, Singapore.
Written informed consent was obtained from all participants prior
to commencing study related activities.
An independent study monitor was appointed by the sponsor
to: 1) review all aspects of the protocol and documentation before
study commencement; 2) to evaluate clarity and consistency of
information entered into database during the trial; and 3) to ensure
completeness of documentation at the end of the trial. Safety of
participants was monitored throughout the study by investigators.
All adverse events were documented, evaluated as to whether they
were expected to occur, determined as serious (death, life threat-
ening, involves hospitalization, results in incapacitation, congenital
anomaly/birth defect, or any event that is medically signiﬁcant) or
non-serious (all other adverse events not corresponding to the
deﬁnition of serious events), and assessed for relationship with the
study beverage by a physician. Serious adverse events (regardless of
relationship with study beverage) were promptly reported to DSRB
and the sponsor, and followed up until the outcome was known.
The study is registered at the US National Institute of Health
clinical trial registry accessible at https://clinicaltrials.gov/
(NCT01738399).
2.3. Study beverage
2.3.1. Formulation and production
The Nestle Research Center (NRC) in Lausanne, Switzerland, and
the Nestle Product Technology Centre (PTC), Orbe, Switzerland,
formulated the placebo and coffee beverages. The placebo beverage
was formulated with the aim to look, taste, and smell like coffee.
Each sachet of the coffee beverage, contained 26.3% of regular
Nescafe mixed with 73.7% of a non-dairy creamer (Table 1). Nestle
Nescafe was produced in the Shah Alam factory (Malaysia). The
Nescafe recipe consists of 100% Robusta coffee (Table 1). Each
sachet of the placebo beverage, contained 32.5% of a colored non-
dairy creamer mixed with 67.5% of the same non-dairy creamer
used for the coffee beverage (Table 1). Both the coffee and the
coffee-like beverage contained 30 kcal per sachet.
Sachets were labeled with expiration date and randomization
code for each subject. All boxes were kept under lock and key at
room temperature in a storeroom at the study site.
2.3.2. Instructions for consumption of the study beverage
Study beverages were distributed to participants at baseline and
on their second clinic visit in the 12th week. Participants were
instructed on the preparation of the beverage and to consume 4
cups of coffee (or placebo) per day for 24 weeks [at breakfast, one
mid-morning, onewith lunch, and one after lunch, with the last cup
being consumed no later than 8:00 p.m.]. If participants missed a
drink, they were advised to combine the missed dose with the next
scheduled drink. Participants were allowed to adjust the amount of
added water according to their preferred coffee strength.Table 1
Composition of study beverages in the Coffee for Metabolic Health (COMETH) study.
Study beverage Formulation
Treatment Regular Nestle Nescafe
Non-dairy creamer (Coffee mate light)
Placebo Colored non-dairy creamer
Non-dairy creamer (Coffee mate light)Participants were also allowed to add sweeteners or milk to the
study beverage if they wished to do so but were instructed to add
the same amount each time and report the amount.2.4. Study population
Study staff ensured that potential participants complied with all
inclusion criteria and possessed none of the exclusion criteria
before enrolling individuals as study participants.2.4.1. Inclusion criteria
All individuals had to comply with all the following inclusion
criteria before they were considered for recruitment:
Individuals of Chinese, Malay or Asian Indian ethnicity
Aged 35 to 69 years
Individuals should have a non-diabetic fasting plasma glucose
concentration (<7.0 mM).
Body mass index 22.5 to 35.4 kg/m2
Users of at least 1 cup of caffeinated coffee per day and who are
willing to be randomized to any of the two intervention groups.
Individuals should be willing to stop consuming caffeinated soft
drinks or supplements during the study and to drink coffee with
non-dairy creamer.
Non-smokers (<1 cigarette per week)
Participants must have been weight stable for at least 8 weeks
preceding the screening visit (±2.5 kgs).2.4.2. Exclusion criteria
Individuals representing one or more of the following criteria
were excluded from participation in the study:
Individuals deemed as being insulin-sensitive during the
screening visit with a HOMA-IR of <1.30.
Any condition or illness that may affect study outcomes or
would make participation potentially harmful such as preg-
nancy or breastfeeding, diabetes mellitus, heart disease, stroke,
hypertension, malabsorption syndromes, gastroesophageal
reﬂux disease (GERD), a history of ulcer, clotting or bleeding
disorders, allergy to the test beverage and allergy to insulin,
according to a detailed medical history.
Participants who had food allergies were excluded based on the
investigator's discretion.
Participants who consumed more than 2 alcoholic servings/day
on a regular basis and >8 caffeinated beverages (i.e. tea and
coffee) per day.
Individuals who had a history of substance abuse or use of
medications that could interferewith the intervention including
bronchodilators, quinolone antibiotics, monoamine oxidase in-
hibitors, anxiolytics, ranitidine, corticosteroids, growth hor-
mone and anti-hypertensives. These conditions were screened
based on subject reporting. Potential participants were asked to
bring in their current medications at the time of screening, and
these were checked by study-staff.% Amount per sachet Caloric content
26.3% 30 kcal/sachet
73.7%
32.5% 30 kcal/sachet
67.5%
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herbal or dietary supplements that could have affected study
outcomes.
Individuals who could not be expected to comply with the study
procedures.
Individuals who were participating in another trial or partici-
pated in another clinical trial during the 12 weeks prior to the
beginning of our study.
Premenopausal women with self-reported irregular menstrual
cycles or peri-menopausal women.2.4.3. Recruitment
Rolling recruitment was employed in our study. Recruitment
efforts were ﬁrst directed towards overweight, coffee drinking men
and women in ongoing cohort studies such as the Singapore Con-
sortium of Cohort Studies (SCCS) [13] and the Singapore Indian Eye
Study-2 (SINDI-2) [14], who gave prior consent to be re-contacted.
Participants were also recruited from the Singaporean Chinese,
Malay and Indian communities through newspaper advertise-
ments, and word-of-mouth methods. Further recruitment efforts
included distributing study leaﬂets into mailboxes at various resi-
dential districts and door-to-door enquiry about interest in the
study. Distribution of leaﬂets and enquiries about participant in-
terest was also done at places of worship, community centers, taxi
stands, malls and food centers, and various medical and health
screening centres. Additionally, we engaged people through
healthy lifestyle or active ageing programmes conducted by com-
munity centers and articles in community center newsletters.
Finally, we encouraged enrolled individuals to refer other potential
participants to the study. Most of the participants of our study were
identiﬁed through responses to newspaper advertisements.
Our study staff administered a brief screening questionnaire
over the telephone to persons who had responded positively to our
recruitment efforts to conduct an initial eligibility assessment. In
addition, a brief description of the study procedures was conveyed
to the individuals.
2.4.4. Screening
Participants were provided information sheets describing the
study and its possible risks and beneﬁts. The screening process
involved consent taking, reviewing medical history and lifestyle
habits, measurements of blood pressure, heart rate, height and
weight, a spot urine sample to rule out pregnancy (for women), and
a fasting blood sample for measurement of glucose and insulin
concentrations. We calculated the HOMA-IR score as [(fasting
glucose  fasting insulin) ÷ 22.5] [12] (Fig. 1). Participants were
excluded if the HOMA-IR score was <1.30. This cut-off corre-
sponded to the 50th percentile of the HOMA-IR values in a Singa-
porean population-based cohort [Singapore Prospective Study
Program (SP2)] [15]. At the commencement of trial, we had used a
HOMA-IR threshold of 2.20 (corresponding to the 75th percentile of
the SP2 cohort) but this was altered to 1.30 under the direction of
our sponsor in view of difﬁculties encountered in participant
recruitment. The HOMA-IR is an indicator of insulin resistance that
is reasonably well correlated with values obtained by glucose
clamps [16]. Individuals were enrolled after having fulﬁlled all in-
clusion criteria, presenting none of the exclusion criteria as
assessed during the screening visit.
2.4.5. Subject withdrawal during the run-in period
As assessed by study investigators, individuals were withdrawn
during the run-in period of the study in the event of: 1) illness, after
examination by the medical staff; 2) lack of compliance; 3) obser-
vation of exclusion criteria, and; 4) subject's decision. Individualswho withdrew before baseline were replaced in order to achieve
enrolment of 130 participants commencing intervention at
baseline.
2.5. Timeline of study visits
After screening, eligible and consented individuals were asked
to avoid caffeine or coffee containing products and medications, or
medications that may interact with caffeine for one month prior to
the start of the study as part of the run-in phase and for the entire
duration of the study. The purpose of the run-in phase was to
gradually wean participants from coffee to facilitate adequate
washout, assist with adherence to study protocol which required
participants to not consume non-study caffeinated foods and bev-
erages, and to minimize differential dropout rates between the
placebo and the intervention arms. In addition, to reduce symp-
toms related to caffeine withdrawal, we advised participants to
gradually reduce their coffee consumption at the start of the run-in
period over a duration of 1 week.
Participants were invited for an orientation session prior to the
run-in-phase during which the conduct of the study was described
in detail. During the 30 min orientation visit, participants were
given a study manual and a urine jug for the collection of ﬁrst
morning urine on the day of baseline clinic visit. Study staff
reminded participants of the commencement of the run-in phase
over the telephone. In addition, study staff contacted participants
one day prior to the baseline visit to deliver further instructions
with regards to fasting and collection of urine for baseline visit
(Fig. 1).
Following the orientation visit, there were three clinic visits
(baseline, week-12, week-24). Week-12 and week-24 visits will
henceforth be referred to as “Mid” and “End” visits respectively.
Pre-menopausal womenwere scheduled at the same phase of their
menstrual cycle for all three clinic visits. Participants were
instructed to come in after an overnight fast and stop drinking
caffeinated beverages including coffee after 8:00 p.m. on the day
before clinic visits. In addition, participants were instructed to
collect ﬁrst-morning urine samples in the jugs provided before
each clinic visit (Fig. 1). When distributing study beverage sachets,
participants received instructions about the consumption of study
beverage (coffee/placebo).
Data on anthropometrics, body fatness, blood pressure, and
heart rate, were obtained, and fasting blood samples were collected
at each clinic visit. A hyperinsulinemic euglycemic clamp was
performed at the baseline and end clinic visits. Participants were
instructed to complete questionnaires related to their diet, physical
activity, gut health andmental well-being at each clinic visit (Fig.1).
Information on adverse events and concomitant medication were
obtained during each clinic visit. After the baseline and mid clinic
visits, participants were given a study diary and sufﬁcient study
beverage sachets to last them for the next 3 months. In addition,
participants were instructed to return unused study beverage sa-
chets and the completed study diary at themid and end clinic visits.
Participants were regularly contacted over the telephone to discuss
concerns and provide motivation to encourage their continued
participation in the study.
2.6. Randomization and intervention allocation
Two lists of 70 individual non-speaking randomization codes
(e.g. 3K5, 7W4), were created for coffee and placebo products by a
biostatistician at NRC. Both lists were given to a product manager at
the Nestle Product Technology Centre (PTC) who assigned one list
as the coffee product codes and the other list as the placebo product
codes. The product manager at Nestle PTC was therefore unblind.
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the coffee or placebo group by means of minimization method of
randomization [17] based on gender and ethnicity (Malay, Chinese
or Indian) as stratiﬁcation factors. Using this strategy, the ﬁrst
participant was truly randomly assigned to either coffee or placebo.
Intervention allocation for subsequent participants were made
dynamically to minimize imbalance between the two intervention
arms with regards to each level of the above-mentioned stratiﬁ-
cation factors. Randomization was performed at the study site us-
ing a secure online “TRIALSYS” system (developed internally at
NRC). In order to randomize a subject, study staff responsible for
distributing the product box (containing sachets of coffee or pla-
cebo) entered the subject's gender and race (Chinese, Malay or
Indian) in the TRIALSYS system to generate a randomization code.
The product box with the assigned randomization code was then
located before the study beverage sachets in it were distributed to
participants. The biostatistician responsible for creating the
randomization codes and conﬁguring “TRIALSYS” at NRC was semi-
blind [possessing knowledge of which participants belonging to
one intervention group or the other but not the identity (coffee or
placebo) of the groups]. However, these individuals (biostatistician
at NRC, product manager at PTC and product distributor at study
site) were not involved in any other study tasks besides their pri-
mary tasks. The rest of the research staff (including investigators,
project manager, other biostatisticians, data managers, clinical
project manager, monitor, and laboratory analysts) involved in the
conduct of the study were truly blind.
2.7. Physical examination
Physical examinations including anthropometric measure-
ments, blood pressure measurements, and blood and urine
collection were performed according to a standardized protocol at
baseline, mid and end clinic visits. Participants were measured in
thin, light clothes in the morning typically from 8:00 a.m. to 9:00
a.m. Study subjects were instructed to visit the washroom before
commencement of measurements. Without footwear, body weight
was measured to the nearest 0.1 kg using a SECA 708 digital scale
(Hamburg, Germany). Height was measured to the nearest centi-
meter without footwear using a SECA 708 height gauge (Hamburg,
Germany). Waist and hip circumferences were measured under the
subjects' clothes using a Butterﬂy brand measuring tape (China).
Waist circumference was measured to the nearest centimeter
midway between the lowest rib margin and the iliac crest. Hip
circumference was measured to the nearest centimeter over the
greater trochanters, perpendicular to the length axis of the body.
Wemeasured triceps, biceps, subscapular and supra-iliac skin-folds
over the right side of the body in triplicates to the nearest milli-
meter using the Holtain Tanner/Whitehouse Skinfold Caliper
(Crymych, Pembrokeshire, Wales, United Kingdom). Bio-
impedance measurements such as fat free mass and fat mass
were carried out to the nearest 0.1 kg according to manufacturer's
recommendations using the Tanita Body Composition Analyzer
TBF-300 (Tokyo, Japan).
With participants seated upright, systolic and diastolic blood
pressure measurements were performed to the nearest millimeter
of mercury (mmHg) in duplicates while heart rate was measured in
duplicates to the nearest beat per minute (bpm) using the Omron
blood pressure and heart rate monitor HEM-7203 (Kyoto, Japan).
Participants were instructed to fast overnight for at least 10 h
prior to blood draw. At baseline, mid and end clinic visits, 35 ml of
fasting blood was obtained by venipuncture for the analyses of
fasting glucose, insulin, triglycerides, HDL, LDL and total choles-
terol, alanine and aspartate aminotransferase, interleukin-6 (IL-6),
IL-18, fetuin-A, total adiponectin, C-reactive protein, and non-esteriﬁed fatty acid levels. Fasting glucose levels were measured
by an enzymatic method (GLU Reagent OSR6221), triglycerides
were assessed by a colorimetric method (TRIG Reagent OSR61118),
HDL-cholesterol was measured by a colorimetric method (HDL-C
Reagent OSR6287), total cholesterol was determined in a colori-
metric assay (CHOL Reagent OSR6116), alanine (ALT IFCC Reagent
OSR6107) and aspartate (AST Reagent OSR6209) aminotransferase
levels were determined by enzymatic assays, and C-reactive protein
was measured in an immunoturbidimetric assay (CRP Latex Re-
agent OSR6199) in a AU5800 analyzer (Beckman Coulter, Brea, CA,
United States). Insulin levels were determined by a sandwich
immunoassay using ADVIA Centaur XP 02230141 (Siemens Medical
Solutions Diagnostics, Tarrytown, NY, United States). LDL-
cholesterol was estimated using the Friedewald's formula:
LDL ¼ TC  HDL TG5 ; where LDL is LDL-cholesterol; TC is total
cholesterol; HDL is HDL-cholesterol and TG is triglycerides [18]. IL-6
(HS600B, R&D Systems, Inc, Minneapolis, MN, United States), IL-18
(7620, MBL International Corporation, Woburn, MA, United States),
fetuin-A (DFTA00, R&D Systems, Inc, Minneapolis, MN, United
States), and total adiponectin (RD195023100, BioVendor, Inc, Czech
Republic) were measured using enzyme-linked immunosorbent
assays on the EVOLIS™ System (Bio-Rad Laboratories, Inc, Hercules,
CA, United States). Non-esteriﬁed fatty acids (434-91795 & 436-
91995, Wako Chemicals GmbH, Neuss, Germany) were measured
by an enzymatic colorimetric method in the Cobas C111 analyzer
(Roche, Basel, Switzerland). During hyperinsulinemic euglycemic
clamp at baseline and end visits, a further 5 ml of blood was drawn
at 0, 90 and 120 min time points to determine fasting and steady
state insulin levels. On the night before each clinic visit, partici-
pants were instructed to empty their bladder before going to bed. In
the morning, participants were instructed to collect their ﬁrst-
morning urine in the bottles provided to them as soon as they
woke up. Participants were also advised to collect urine passed in
the middle of the night into the same bottle. About 18 ml of the
ﬁrst-morning urine was collected primarily for the analyses of
creatinine and 8-isoprostane.
2.8. Questionnaires
We collected information on lifestyle (diet and physical activity),
mental health (depression and fatigue), and gut health at baseline,
mid-study, and the ﬁnal study visit using standardized question-
naires. A validated [19] food frequency questionnaire (FFQ),
adapted from the Singapore National Nutrition Survey 2010 [20],
was used to assess dietary intakes over the past month. Dietary
information obtained included intakes of a wide variety of foods
and, alcoholic and non-alcoholic beverages. To assess physical ac-
tivity in the last seven days, the validated [21] International Phys-
ical Activity Questionnaire (IPAQ) (short version comprising 4
generic items) [22] was administered. The interviewer-
administered IPAQ consisted of queries regarding light, moderate
and vigorous physical activities during leisure, transportation, at
work, and in the household.
To assess mental health over the past week, participants self-
administered a validated [23] 20-item Center for Epidemiological
Studies Depression Scale (CES-D) [24] questionnaire. The CES-D
evaluates the most noticeable signs of depression in the general
population such as feelings of hopelessness, guilt and worthless-
ness. Each item on the CES-D is scored on a four-point scale and the
sum of all scores ranges from 0 to 60. High scores suggest a high
level of distress while low scores suggest a low level of distress.
Fatigue over the past week was assessed using the self-
administered 7-item Patient Reported Outcomes Measurement
Information System (PROMIS) fatigue scale short form [25,26]
questionnaire which has been validated in women with
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Gut health over the past week was evaluated using a self-
administered questionnaire adapted from bowel health compo-
nent of the National Health and Nutrition Survey (NHANES) [29,30]
and the Irritable Bowel Syndrome-Symptom Severity Scale (IBS-
SSS) [31]. The gut health questionnaire entailed queries on fre-
quency of bowel movements, type of stool, history of constipation
and diarrhea, and abdominal discomfort. All questionnaires were
administered at baseline, mid and end visits.
2.9. The hyperinsulinemic-euglycemic clamp
The hyperinsulinemic-euglycemic clamp [32] is regarded as the
gold standard method of evaluating insulin sensitivity in humans
[33] that offers the most direct measurement of insulin-mediated
glucose disposal under steady state conditions in vivo [12]. A 2-h
hyperinsulinemic euglycemic clamp procedure was carried out
after an overnight fast. During the clamp procedure, participants
were intravenously saturated with exogenous insulin at a high
infusion rate (40 mU of insulin per m2 of body surface area per
min). This results in increased glucose disposal [uptake into pe-
ripheral tissues; mainly skeletal muscles (~85%)] [34] in vivo while
hepatic glucose production is suppressed. Concurrently, exogenous
glucose was infused to replenish the increased glucose disposal
mediated by insulin infusion. Using a bedside glucose analyzer (YSI
Incorporated, USA), the rate of glucose infusion was adjusted at 5-
min intervals to maintain euglycemic levels (5.0 mmol/L). Blood
samples were obtained at 0, 90 and 120 min to determine plasma
insulin levels for HOMA-IR and metabolized glucose (M-value)
computations. By maintaining a euglycemic steady-state, the rate
of glucose infusion would reﬂect the rate of systemic glucose
disposal into peripheral tissues such as skeletal muscles. Therefore,
individuals with slower rates of glucose infusion (i.e. lower M
values) are acknowledged to be more resistant to insulin than in-
dividuals with faster rates of infusion.
The GIR over the ﬁnal 30min of the clamp procedure reﬂects the
steady-state glucose disposal rate (GDR) or metabolizable glucose
(M-value). The M-value is the measure of insulin sensitivity of the
clamp procedure and it is typically standardized to body weight
(Kg) or fat free mass (Kg); less frequently to body surface area (m2)
or metabolic size (KgFFM þ 17.7) [35]. In addition to the M-value,
the M/I ratio, known as the insulin sensitivity index of euglycemic
clamp, is frequently reported. The M/I ratio (amount of glucose
metabolized per unit of plasma insulin) [36] is obtained by
normalizing the M-value with the average plasma insulin levels
during the ﬁnal 30 min of the clamp procedure (also known as
steady-state plasma insulin levels) [37]. Average steady-state in-
sulin levels were calculated by averaging the 90 and 120-min
plasma insulin values.
In this study, the primary outcome refers to the amount of
glucose metabolized (M-value) per kilogram of body weight per
minute (mg kg1 min1) (Mbw). The decision to adjust the M-value
to bodyweight instead of fat free mass (FFM) stems from the con-
troversy about the extent of glucose disposal in adipose tissue [38];
studies have shown glucose uptake to be possible in adipocytes
under insulin mediated conditions in vivo [34]. Furthermore, FFM,
as determined by bio-impedance analyses has been shown to
overestimate and underestimate FFM in lean and obese individuals
respectively as compared to the gold standard Dual Energy X-Ray
Absorptiometry (DXA) [39]. The M/I ratio, in this study, refers to the
percentage of the amount of glucose metabolized per kilogram of
bodyweight per minute standardized to per unit of steady state
plasma insulin levels (100  mg kg1 min1 mU1 L1) [36].
However, due to the higher degree of variability in the M/I ratio as
compared to M-value, normalizing the insulin sensitivity measureto steady state plasma insulin levels during glucose clamps may not
be advantageous [40]. Therefore, the M-value adjusted to body-
weight (Mbw) will be the primary outcome of our study while the
M/I ratio (M/Ibw) will be reported in secondary analyses. In addi-
tion, the FFM-adjustedM-value (Mffm) and M/I ratio (M/Iffm) will be
evaluated in secondary analyses.
Typically, a correction factor, termed ‘space correction’ by
DeFronzo et al. [32], is applied to the M-value to correct for non-
insulin mediated glucose uptake and changes in glucose infusion
rate that are not due to real changes in glucose disposal. Space
correction for a 30-min steady-state is calculated as (G2  G1) x
0.06333; where G2 and G1 are plasma glucose concentrations (mg/
dl) at the end and beginning of the 30-min time period, respectively
[34]. The space corrected M-value is then obtained using
MSC¼M SC UC; whereMSC is the space correctedM-value;M is
the uncorrected M-value; SC is the space correction factor; and UC
is the correction factor for urinary glucose loss. Urinary correction is
negligible as urinary glucose loss does not generally occur during
clamp procedures performed at euglycemia [34].
For valid insulin sensitivity assessment, the quality of clamp
data was taken into account in the analyses of the M-value and M/I
ratio. Individuals who had not fasted before the glucose clamp
(with fasting glucose 7.0mmol/L and fasting insulin >50mU/L) or
possessed steady state plasma insulin levels that were not adequate
to suppress hepatic glucose production (<50 mU/L) were excluded
from the analyses of the M-value and M/I ratio [34].
During the study, there was a change in the assay (to the UniCel
DxI Immunoassay System, Beckman Coulter, Brea, CA, United
States) used to measure insulin levels. The agreement between the
two assays used for these insulin measurements were high
(r2 ¼ 0.97) in a calibration study using 30 individuals and we
calculated the expected older assay values for samples measured
with the newer assay using the following formula:
old0 ¼ eð0:012þ0:948ln newÞ; where old’ is formula-derived old assay
value; and new is the insulin value measured under the new assay.
2.10. Compliance assessments
A variety of strategies were employed to identify non-
compliance in our study. The 4-week run-in phase of coffee
intake abstention allowed precipitation of non-compliance among
potential participants who were unable to refrain from coffee
consumption. Individuals who dropped out of the study at this
stage did not affect our dropout rate because they were yet to be
enrolled and randomized.
During the trial phase, counting of returned unused sachets at
mid and end clinic visits was used to assess compliance. Adherence
to study protocol was encouraged by study staff by regular phone
calls. During the orientation visit, participants were providedwith a
wallet insert card containing information about coffee/caffeine
containing foods to avoid. The wallet insert contained contact in-
formation of study staff should the participant need clariﬁcation.
A study diary was provided to the participants at baseline clinic
visit. In the course of the 24 weeks of intervention, participants
were instructed to record the number of sachets consumed on a
daily basis in their study diary. Participants were also instructed to
record any coffee/caffeine containing food/medicine consumed.
The study diaries were checked on the week 12 and week 24 clinic
visits. Any discrepancies were clariﬁed with the participant during
the clinic visit.
Questions regarding consumption of coffee/caffeine containing
foods or beverages in the past one month were also included in the
FFQ. Study staff evaluated compliance from the answers provided.
Together with the physical activity questionnaire, the FFQ also
serves to monitor changes in lifestyle during the intervention
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We will also measure chlorogenic acid metabolites in plasma
using reversed-phase ultra-performance liquid chromatography
(Acquity, UPLC BEH C18 column, Waters AG, Baden-D€attwil,
Switzerland) electrospray ionization-tandem mass spectrometry
(Triple QUAD 5500 System, AB Sciex, Zug, Switzerland). Coffee is
the major source of chlorogenic acid in the diet, but various fruits
and vegetables also contain chlorogenic acid [41]. As a result,
plasma chlorogenic acid metabolites will not be a good measure of
compliance on an individual level, but differences in concentrations
between the coffee and the placebo group will be used to assess
compliance at a group level.
2.11. Quality control of laboratory analysis
To ensure that laboratory measurements did not vary substan-
tially within and across batches, we collected fasting blood and
overnight urine samples in a convenience sample of 15 people to
serve as quality control (QC) samples. Written informed consent
was obtained before a brief screener was used to assess the eligi-
bility of participants. Participants were between 21 and 69 years old
with Malay, Chinese or Indian ethnicity. Persons who regularly
smoked (1 cigarette/week or more) or had heavy alcohol con-
sumption (>2 drinks/day) or antibiotics use in the past 3 months
and those with pre-existing diabetes mellitus, heart disease, stroke,
hypertension, clotting or bleeding disorders, and women who re-
ported to be pregnant or breastfeeding were excluded.
Participants were instructed to fast for at least 10 h prior to their
blood draw. Participants who were also willing to provide an
overnight urine sample were provided with a urine jug and in-
structions on how to collect overnight urine.
2.12. Data analysis and statistics
2.12.1. Sample size calculations
The sample size calculations were based on the anticipated
mean difference in ﬁnal M/Iffm between the intervention and con-
trol arms. Given the design of our study, the sample size formula for
a statistical superiority trial design [42] was used:
N ¼ 2 ðz1a=2 þ z1b=dÞ2  s2; where N is the sample size per
group; z1-a/2 is the z score for a 2-tailed test at 5% signiﬁcance level;
z1-b is the z score at a statistical power of 80%; d is the anticipated
mean difference in the absolute M/Iffm between the coffee and
placebo groups at 24-week and s is the standard deviation which is
assumed to be common for both groups.
Given that there have been no previous trials of the effect of
coffee on clamp measured insulin sensitivity, the anticipated mean
difference in M/Iffm was obtained from an article by McAuley et al.
[38] on the inﬂuence of a lifestyle intervention on insulin sensitivity
in normoglycemic insulin resistant individuals. After 4 months of
an intense diet and exercise intervention, McAuley et al. [38]
observed a 1.2 mg kg1 min1 mU1 L1 difference in ﬁnal M/Iffm
between the intervention and control groups. Based on their data
we estimated a corresponding SD of 2.19 mg kg1 min1 mU1 L1.
Therefore, at 80% power and 5% signiﬁcance level, we obtained
N ¼ 2 ð1:96þ 0:84=1:2Þ2  2:192z52. We thus required 52 in-
dividuals per intervention group with a total of 104 individuals.
This number will be achieved if 17% or fewer of the 126 participants
who completed our baseline assessment drop out.
2.12.2. Analysis of baseline characteristics
Given that two enrolled individuals did not complete baseline
assessment, 126 out of the 128 enrolled participants were included
in baseline analyses. Nominal scale variables were described as
percentages and compared using chi-square tests. Normallydistributed interval and ratio scale variables were described as
mean and standard deviation, and compared using student's T-test
with equal variances. Interval ratio scale variables with skewed
distributions were described as median and interquartile ranges,
and compared using Mann-Whitney U tests. For baseline analyses
of clamp-based insulin sensitivity measures (M and M/I ratio), an
additional 4 participants with invalid clamp data (subjects with
steady state insulin levels there were not sufﬁciently high to
adequately suppress hepatic glucose production) out of the 126
enrolled subjects with baseline data were excluded.
2.12.3. Analysis of the effect of coffee on primary outcomes
The primary outcome was the difference between coffee and
placebo groups in Mbw at the end of the study corrected for the
baseline Mbw values. Our null hypothesis is that consumption of 4
cups of coffee per day for 24 weeks will not inﬂuence changes in
insulin sensitivity. Under this hypothesis, we expect to ﬁnd no
signiﬁcant difference betweenMbw values of the coffee and placebo
groups at the end of intervention after adjusting for baseline Mbw
values. The alternative hypothesis is that individuals receiving the
coffee beverage will experience an increase in insulin sensitivity.
Under this hypothesis and with sufﬁcient statistical power, we
expect to ﬁnd a signiﬁcant improvement in insulin sensitivity, as
indicated by the signiﬁcantly higher Mbw values among individuals
in the coffee group compared to the placebo group at week 24.
As indicated in the Consolidated Standards of Reporting Trials
(CONSORT) [43] statement, results from an unadjusted analysis (t-
test comparing the difference in mean Mbw between the placebo
and coffee groups at week 24) will be ﬁrst reported. The difference
in the mean Mbw at week 24 will further be adjusted for the
baseline Mbw using Analysis of Covariance (ANCOVA) with treat-
ment as the main effect and baseline Mbw as a covariate. Log
transformation of the Mbw values will be performed as needed to
achieve normality and equal variances; t-tests with unequal vari-
ances will be performed if log-transformation is insufﬁcient to
ensure equivariance.
Intention to treat (ITT) analysis (regarded as the gold standard
endpoint analysis of randomized trials) on the primary outcome
will be performed according to original assignments at randomi-
zation without taking into account overt dropouts and unplanned
crossovers resulting from silent dropouts and drop-ins (contami-
nation). Only if necessary (depending on compliance of partici-
pants), per protocol (PP) analysis may be done according to
whether coffee was actually consumed (determined from compli-
ance assessments described earlier) during the intervention period.
2.12.4. Analysis of the effect of coffee on secondary outcomes
Secondary outcomes on insulin sensitivity included differences
between coffee and placebo groups in theweek 24 values for M/Ibw,
Mffm and M/Iffm with and without adjustment for their corre-
sponding baseline values. Other secondary outcomes included
differences between coffee and placebo arms at week 12 or week 24
for the following outcomes: fasting glucose metabolism (fasting
plasma glucose, HOMA-IR); potential mediators of effects of coffee
on insulin sensitivity including non-esteriﬁed fatty acids, adipo-
kines and markers of inﬂammation (total adiponectin, C-reactive
protein, interleukins 6 and 18), markers of liver function (alanine
and aspartate aminotransferases, fetuin-A), markers of renal func-
tion and oxidative stress (serum creatinine, urinary 8-isoprostane);
cardiovascular risk factors including heart rate, blood pressure
(systolic and diastolic), and blood lipids (fasting triglycerides, LDL-
cholesterol, HDL-cholesterol); reported gut health (frequency of
bowel movements, type of stool, abdominal pain); and psycho-
logical measures (depression, fatigue).
With the exception of secondary insulin sensitivity outcomes,
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week-12 and week-24 visits. The efﬁcacy of coffee consumption on
the above-mentioned secondary outcomes will be assessed using
mixed models that account for within participant correlated errors.
As an additional analysis, differences in secondary endpoints be-
tween the coffee and placebo groups at week 12 and at week 24will
also be analyzed using ANCOVA with adjustment for baseline
values.2.13. Trial proﬁle
Of at least 2109 phone calls made to individuals who were
identiﬁed through various recruitment activities, 331 individuals
were potentially eligible and interested to participate in the study
(Fig. 2). Of the calls made, 534 individuals were not contactable and
730 were not eligible based on a screening questionnaire admin-
istered over the phone (predominant reasons include medical
conditions such as hypertension or cardiac problems). Upon
learning more about the study, 514 individuals declined participa-
tion because they were either too busy or not interested. Although
screening visits were scheduled for all 331 potentially eligible in-
dividuals, 59 of them either cancelled or did not show up at our
study site. Of the 272 individuals who attended screening, 50 were
deemed as screen failures while 55 did not qualify based on their
screening laboratory results. Screen failures were individuals who
were found to have issues such high blood pressure or ineligible
BMI and were known to be ineligible without a need to draw blood1,778 Excluded 
       534 Not contactable
       730 Not eligible
       514 Not interested 
Phone calls made to 2,109 individuals
331 Eligible and interested 
59 Did not attend scheduled 
screening visit
272 Attended screening visit
105 Not eligible after screening 
      50 Screen failures* 
      55 Not eligible based on  
            screening lab results
167 Eligible after screening
23 Did not complete orientation 
      20 Withdrew after screening 
       3 Not contactable for orientation 
144 Completed orientation
16 Did not complete run-in phase
      6 Withdrew after orientation 
      9 Withdrew during run-in phase
      1 Not contactable after orientation 
128 Enrolled (randomized)
2 Did not complete baseline
      1 Not contactable for baseline
      1 withdrawn at baseline (high B.P.) 
126 Completed baseline
Fig. 2. Trial proﬁle of the Coffee for Metabolic Health (COMETH) study. *Screen failures
were individuals who were found to be ineligible based on criteria such as high blood
pressure and BMI, etc. These individuals were excluded without the need for a blood
sample assessment.for laboratory analyses. The most common reason for screen failure
was the presence of high blood pressure (76.0%). Exclusions based
on screening lab results were mostly (90.9%) due to HOMA-IR
values of less than 1.30.
Of the 167 eligible individuals after screening, 20 withdrew after
the screening visit and 3 were not contactable. The remaining 144
individuals successfully completed their orientation visit (Fig. 2).
After completing orientation, 6 individuals withdrew from the
study while 1 individual was not contactable. Since coffee drinkers
were recruited, a 4-week run in period ensued after orientation in
which participants were asked to refrain from consuming coffee or
other caffeinated products. During the run-in phase, 9 individuals
withdrew from the study. A total of 128 individuals successfully
completed the run-in phase and were enrolled into the study
before the enrolment deadline (Fig. 2). These 128 individuals were
randomized to either the coffee or placebo arm. Although enrolled,
2 subjects did not complete the baseline visit. This was because
early in the study, randomization was done before the baseline
clinic visit. As such, one subject was not contactable although he
had successfully completed the run-in phase and had been ran-
domized. The other subject was found to have high blood pressure
at the baseline visit. After multiple readings, the elevated blood
pressure persisted and an on-site study physician decided to
withdraw the subject from the study. Therefore, a total of 126
participants successfully completed the baseline visit.
2.14. Baseline characteristics
Males formed the majority (57.1%) of our study population with
a median age of 48 years while females had a median age of 47
years. Table 2 shows the baseline characteristics of the participants
according to sex. Most of our participants were Chinese, reﬂecting
the ethnic composition of the general Singapore population.
However, unlike the general population, we had a higher propor-
tion of Asian Indians compared to Malays in our study population.
One reason could be that initially we restricted recruitment to
Chinese and Indian participants but later expanded recruitment to
Malay individuals. Furthermore, in view of the fasting month of
Ramadan, which may interfere with adherence to the study pro-
tocol, we stopped recruiting Malay participants before enrolment
deadline. Majority (65.1%) of our study participants had a history of
consuming 2 or more but less than 4 cups of coffee daily.
Based on BMI recommended for Asian populations [44], par-
ticipants in our study were at least overweight as expected and
stated in the inclusion criteria, with 77.0% of subjects being obese
(25 kg/m2). Medianwaist circumferences (WC) [44,45] and waist-
to-height ratios (WHTR) [46] suggest abdominal obesity among
men (WCmen  90 cm; WHTRmen  0.52) and women
(WCwomen  80 cm; WHTRwomen  0.53). Among commonly
measured anthropometric indices, males had a signiﬁcantly greater
waist circumference and waist-to-hip ratio, whereas females had a
larger hip circumference and BMI (Table 2). Both men and women
had median body fat percentages that were higher than values
typical for the threshold of obesity (BMI of 30 kg/m2) in persons of
European origin (25% for men and 35% for women) [47].
As expected from our exclusion criteria, the median systolic and
diastolic blood pressure values were below cut-offs for high blood
pressure, and all participants had normal heart rates of below 100
beats per minute.
The median levels of total cholesterol, triglycerides, HDL-
cholesterol, aspartate [48] and alanine [49] aminotransferase ac-
tivity levels, and mean levels of LDL-cholesterol were within the
normal range [50]. As expected from our inclusion criteria, median
and interquartile ranges of HOMA-IR suggested that our study
population consisted of individuals who were more likely to be
Table 2
COMETH baseline characteristics by gender for all subjects who completed baseline (n ¼ 126).
Characteristics Males (n ¼ 72) Females (n ¼ 54)
Age (years) 48 (40e55) 47 (41e53)
Ethnicity n (%)
Chinese 50 (69.4) 31 (57.4)
Malay 9 (12.5) 8 (14.8)
Indian 13 (18.1) 15 (27.8)
History of coffee consumption n (%)
< 2 cups/day 17 (23.6) 12 (22.2)
 2 to < 4 cups/day 46 (63.9) 36 (66.7)
 4 cups/day 9 (12.5) 6 (11.1)
Weight (Kg) 78.0 (71.5e83.2) 70.6 (63.6e75.9)
Height (cm) 171.0 (167.5e173.5) 158.0 (153.0e161.0)
Waist circumference (cm) 92.5 (89.0e98.0) 89.0 (81.0e93.0)
Hip circumference (cm) 101.5 (98.5e106.0) 106.0 (100.0e111.0)
Body mass index (Kg/m2) 26.7 (24.9e28.1) 28.4 (25.9e30.4)
Waist-to-hip ratio 0.91 (0.054) 0.83 (0.064)
Waist-to-height ratio 0.54 (0.52e0.57) 0.57 (0.52e0.59)
Skinfold thickness (mm)
Triceps 24.5 (16.1e30.6) 31.0 (27.5e36.3)
Biceps 11.4 (9.3e16.0) 20.2 (15.7e23.6)
Subcapsular 24.2 (19.3e30.1) 28.9 (24.4e32.9)
Supra-iliac 26.8 (21.4e38.4) 30.9 (25.8e35.5)
Fat free mass (Kg) 55.8 (51.6e60.9) 40.7 (38.5e44.4)
Fat mass (Kg) 20.9 (17.3e24.9) 28.7 (23.8e36.0)
Body fat percentage (%) 26.2 (23.5e31.0) 40.3 (35.7e45.5)
Systolic blood pressure (mmHg) 129.0 (122.8e135.0) 122.0 (113.5e129.0)
Diastolic blood pressure (mmHg) 79.0 (72.8e85.3) 75.0 (70.0e82.0)
Heart rate (bpm) 69 (64e76) 74 (70e80)
Total cholesterol (mmol/L) 4.97 (4.57e5.80) 5.26 (4.72e5.94)
Triglycerides (mmol/L) 1.44 (1.04e1.84) 1.05 (0.91e1.40)
HDL-cholesterol (mmol/L) 1.10 (0.98e1.22) 1.36 (1.12e1.59)
LDL-cholesterol (mmol/L) 3.31 (0.80)a 3.30 (0.66)
Aspartate aminotransferase (U/L) 25 (21e28) 21 (18e26)
Alanine aminotransferase (U/L) 29 (24e37) 20 (16e27)
Plasma insulin at 0 min (mU/L) 9.6 (6.7e15.3) 10.4 (5.7e15.8)
Plasma insulin at 90 min (mU/L) 115.6 (80.7e138.5) 108.7 (74.6e130.8)
Plasma insulin at 120 min (mU/L) 111.3 (79.9e136.3) 109.1 (82.5e139.4)
Average steady state plasma insulin (mU/L) 113.2 (79.6e134.4) 107.6 (80.9e130.9)
Fasting plasma glucose (mmol/L) 4.7 (4.6e5.1) 4.7 (4.5e5.1)
Glucose infusion rate (ml/hr) 92.4 (71.6e130.6) 96.4 (74.9e123.7)
HOMA-IR 2.08 (1.44e3.23) 2.19 (1.24e3.24)
M-value (BWc) (mg/Kg/min) 4.10 (3.04e5.56)^ 4.28 (3.44e6.18)b
Space corrected M-value (BW) (mg/Kg/min) 4.11 (3.10e5.53)^ 4.32 (3.64e6.25)b
M-value (FFMd) (mg/Kg/min) 5.83 (4.36e7.92)^ 7.51 (5.95e10.51)b
Space corrected M-value (FFM) (mg/Kg/min) 5.89 (4.35e7.97)^ 7.45 (6.04e10.49)b
M/I ratio (BW) (100  mg kg1 min1 mU1 L1) 3.80 (2.65e6.35)^ 4.40 (2.99e5.78)b
Space Corrected M/I ratio (BW) (100  mg kg1 min1 mU1 L1) 3.90 (2.73e6.35)^ 4.50 (3.01e5.81)b
M/I ratio (FFM) (100  mg kg1 min1 mU1 L1) 5.18 (3.63e8.65)^ 7.00 (5.20e10.73)b
Space Corrected M/I ratio (FFM) (100  mg kg1 min1 mU1 L1) 5.28 (3.64e8.58)^ 7.03 (5.23e10.71)b
Nominal variables described as percentages; normally distributed interval ratio scale variables described as mean and SD; interval ratio scale variables with skewed
distributions described as median and IQR.
a Invalid data from 2 subjects; ^1 subject excluded from analysis due to invalid baseline clamp data.
b 3 Subjects excluded from analysis due to invalid baseline clamp data.
c Body Weight.
d Fat Free Mass.
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moglycemic range with a 3.2% baseline prevalence of impaired
fasting glucose among all subjects [51]. Clamp based insulin
sensitivity measures (M and M/I ratio), when adjusted for body-
weight, indicated that males and females had similar levels of in-
sulin sensitivity. (Table 2).
3. Discussion
In a large number of cohort studies, coffee consumption was
associated with a lower risk for type 2 diabetes [6]. Although most
observational studies statistically address confounding, residual
confounding may persist. Randomized trials are therefore needed
to provide more conclusive evidence. However, to date, few trials
have been conducted to investigate the effect of coffee on glucosemetabolism [7e11]. Furthermore, trials conducted thus far had
limitations such as small sample sizes, lack of randomization or
blinding, short duration of follow-up and use of surrogatemeasures
of insulin sensitivity. Therefore, we designed the COMETH study, a
randomized placebo-controlled 6-month trial that examined the
effect of consuming 4 cups of coffee per day for 24 weeks on insulin
sensitivity assessed with a glucose clamp.
3.1. Recruitment
According to our sample size calculations, we had planned to
recruit and enroll 130 participants after accounting for an expected
dropout rate of 20% to obtain a minimum sample size of 104.
Recruitment for coffee trial was challenging, because it required the
selection of participants whowerewilling to either consume 4 cups
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months. Long-term adherence to coffee consumption requires se-
lection of persons who regularly consume coffee. However, given
the strict inclusion and exclusion parameters, recruitment of sub-
jects proved to be challenging from the commencement of study
activities. As such, we expanded the scope and increased the in-
tensity of recruitment activities and achieved a total enrolment of
128 participants by the enrolment deadline.
3.2. Strengths and limitations
This study had several strengths. Firstly, this study was double-
blinded. Central to masking was the production of a well-designed
placebo beverage that tastes, smells and looks like coffee unlike in
previous trials [8,9], where water was used. This allowed the
aversion of subconscious or conscious preconceptions in in-
vestigators, thereby minimizing diagnostic suspicion bias in the
assessment of insulin sensitivity. In addition, the blinded placebo
group allowed us to account for a possible Hawthorne effect
because lifestyle modiﬁcations, such as those culminating inweight
changes, could inﬂuence insulin sensitivity. Importantly, the pla-
cebo beverage allows for a standardized replacement of coffee,
otherwise, people who typically consume coffee may be tempted to
drink some other beverage (e.g. tea or malt beverages) instead of
water.
This study provided a larger sample size and a longer duration of
intervention and follow up. Previous trials [7e10] were relatively
short ranging from2 to 16weeks with sample sizes ranging from26
to 49 subjects. The longer intervention period with greater statis-
tical power increases the likelihood that we will be able detect
longer term effects of coffee on insulin sensitivity.
An important advantage of this study over previous trials was
the employment of the gold standard measure of insulin sensitivity
(hyperinsulinemic euglycemic clamp) to assess the potential in-
ﬂuence of coffee on the risk of diabetes. Previous trials [7e10] had
relied on surrogate measures such as the HOMA-IR or the Com-
posite Insulin Sensitivity Index (CISI) [52] derived from fasting
glucose and insulin data or data from an oral glucose tolerance test.
The 4-week run-in period not only conferred a washout period
but also enabled us to evaluate long-term tolerance to caffeine
depletion among participants who are habitual coffee drinkers.
Given the relatively longer intervention period compared to earlier
trials, the run-in period was critical in identifying overt non-
compliers who had problems abstaining from coffee consumption
and were likely to drop out from the study should they be enrolled.
Several limitations of our study should also be noted. Because
the extent of glucose disposal in adipose tissues remains unclear,
previous studies based on glucose clamps have typically reported
insulin sensitivity measures standardized to both body weight and
fat free mass [35,38]. In our study, because of logistical reasons, we
did not include ‘gold standard’ assessments of FFM such as DXA
scans and we will therefore only report body weight standardized
M-values as the primary outcome while the M/I ratios and FFM
standardized insulin sensitivity measures will be reported as sec-
ondary outcomes.
Due to methodological reasons (see section 2.9), we decided to
slightly change our primary outcome from M/Iffm to Mbw. It is un-
clear how this change will affect our statistical power. On the one
hand not dividing by insulin values may increase our power as Mbw
is not affected by additional measurement error in the assessment
of insulin concentrations [53]. On the other hand, it may reduce our
power if ﬂuctuations in insulin concentrations during the ﬁnal
phase of the clamp introduce extraneous variation. It is less likely
that the use of body weight instead of fat free mass in the calcu-
lation will have a substantial impact as we do not expect the coffeeintervention to affect body composition.
Although this study required abstention from coffee consump-
tion, covert non-compliance (silent drop outs or drop-ins) is a
possibility given the ubiquitous availability of coffee. Inadvertent
consumption of coffee among placebo group subjects or abstention
of study product use among coffee group subjects could potentially
diminish the effect of coffee in our study. We employed several
strategies to assess compliance bias such as counting of unused
study beverage sachets and the use of a study diary. Still, these
methods rely on cooperation of subjects and complementary
objective biomarkers of compliance would have been preferable.
Unfortunately, identifying biomarkers that speciﬁc to coffee proved
to be difﬁcult. Chlorogenic acid metabolites, although not speciﬁc
to coffee, will bemeasured and used as amarker for compliance at a
group level.
Incomplete blinding is a possibility because our recruited par-
ticipants are habitual coffee drinkers who could recognize the ef-
fects of caffeine. At the end of the study, we will ask subjects to
guess which arm they had been randomized to and this will inform
us whether blinding was successful.
Given the randomized controlled and double-blind nature of
our trial, themeasurement error in insulin sensitivity assessment in
participants is unlikely to differ between the coffee and the placebo
group. As a result, this measurement error is likely to underesti-
mate the treatment effect.
Finally, we investigated the possible efﬁcacy of coffee in
improving insulin sensitivity in a population consisting of non-
diabetic, non-smoking, Chinese, Malay and Asian Indians. As a
result, our results may not be generalizable to persons with dia-
betes, smokers, or other ethnic groups.3.3. Interpretation of outcomes
There are three possible outcomes in our study. Firstly, we may
ﬁnd no difference in insulin sensitivity over the 24-week period
between the placebo and coffee groups. This would suggest that
there is no evidence of coffee's beneﬁcial inﬂuence on insulin
sensitivity. One explanation could be that our study was not sufﬁ-
ciently powered or the follow duration was not long enough to
observe the appreciable effects of coffee on insulin sensitivity.
Another explanation could be that the association seen in obser-
vation studies could have been due to coffee modulating diabetes
risk through pathways other than that involving insulin sensitivity.
A null ﬁnding could also indicate that coffee may act in a later stage
of diabetes development when individuals are more insulin-
resistant or have pre-diabetes.
Secondly, we may ﬁnd that the improvement of insulin sensi-
tivity in the placebo group is signiﬁcantly greater than the coffee
group. Such a result would be in conﬂict with our hypothesis that
coffee could reduce diabetes risk. A previous report had indicated
that caffeine adversely affects glucose metabolism by reducing in-
sulin sensitivity following acute administration [54]. So, an increase
in insulin resistance among the coffee group could reﬂect a long
term persistent adverse effect of caffeine on glucose metabolism.
Thirdly, wemay ﬁnd that the improvement of insulin sensitivity
in the coffee group is signiﬁcantly greater than the placebo group.
This would corroborate the abundance of observational studies in
which coffee consumption was inversely associated with risk of
type 2 diabetes. Such a result would suggest that 24 weeks of daily
coffee intake is sufﬁcient to improve insulin sensitivity. Impor-
tantly, this evidence would suggest that coffee modulates type 2
diabetes risk through biological mechanisms that involve insulin
sensitivity.
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As of October 2015, enrollment of participants and data collec-
tion are complete. Data analysis is ongoing.
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